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difference has been found when examining individual
cancers. Inter-domain correlations in each of the three
versions of the QLQ-C30 were strongest in Role Func-
tioning, Pain and Global Health Status. Cronbach’s reli-
ability measure shows improved reliability in newer ver-
sions of the questionnaire, for example, the pain scale
increases from 0.82 to 0.86 from version 1 to version 3.
CONCLUSION: We believe this is one of the first studies
to examine the scales of all three versions of the QLQ-
C30 with a large sample across a large number of coun-
tries and cancer sites. We found that in general all three
versions of the QLQ-C30 have similar psychometric
structures, that the measure proves to a be a useful tool
to use within a clinical trial setting and that missing data
is continually reducing over time, indicating increasing
compliance among staff/patients.
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OBJECTIVE: Quality of life (QOL) is becoming an ac-
cepted endpoint in cancer clinical trials. However, reports
suggest that fewer than 10% of clinical trials include QOL
assessment, it is believed that such reports may be biased
by time lag. This paper examines the extent of QOL stud-
ies that are conducted within one of the largest academic
cancer clinical trial organizations in Europe.
METHOD: Examination of all clinical trials conducted
by the EORTC (between 1990 to 2000) was undertaken
by reviewing databases, records and publications. Trials
were systematically selected if they involved any aspect of
QOL assessment. The protocols were then evaluated us-
ing criteria that evaluated the quality of trial designs and
methodology employed.
RESULTS: In total, 112 clinical trials involving over 10,000
patients were identified as having a QOL component. All
trials involved multinational patient recruitment, with the
highest recruitment from the Netherlands, France and Ger-
many, and lowest from Malta, Estonia and Slovakia. Ap-
proximately 25 disease groups have been actively recruiting
patients from disease groups of genito-urinary, breast and
lung cancers. A clear linear trend was noted, with increasing
numbers of clinical trials involving QOL components over
this period. Of these trials, 74 studies were Phase III, 15
Phase II and the remainder were feasibility studies. Pres-
ently, 45 trials are ongoing, 19 almost ready for data analy-
sis, 15 published and 10 being analyzed. In the last year, 30
studies involving QOL assessment have been submitted for
research, suggesting that QOL is a highly important end-
point in trials throughout Europe
CONCLUSION: While a decade ago QOL was not a ma-
jor component of EORTC clinical trials, it is now highly
integrated into trials, almost a standard secondary end-
point. In the European context, this suggests that clini-
cians and researchers are increasingly seeing the impor-
tance of patient-based outcome assessment methods.
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OBJECTIVE: Recommendations on the appropriate use
of corticosteroids (cort) and HT-3 antagonists (HT3A),
alone or in combination with benzodiazepines (benz) and
dopamine receptor antagonists (dopA) vary between
three and nine different anti-emetic strategies.
METHODS: We retrospectively compared the use of
anti-emetics in our clinical practice with the consensus
recommendations of Peruggia. We analyzed all patients
from a single department unit receiving chemotherapy on
an inpatient basis in February 2000.
RESULTS: One hundred thirty five days of chemother-
apy in 38 patients (20–78 years old, male/female 1,7/1)
suffering from various malignant diseases were included.
Five patients (13.1%) received anti-emetic therapy for
other reasons than preventing nausea and vomiting (e.g.
corticosteroids as comedication with paclitaxel). We
grouped the chemotherapy protocols as follows: very low
risk, (n  5); low risk, (n  44); moderate risk, (n  16);
high risk, (n  40); and severe risk, (n  30), according
to the Peruggia guidelines. We calculated the total theo-
retical consensus-guided costs for anti-emetic treatment
to be 2079.04 Deutsche Marks (DM) and the real costs
to be 2024.93 DM (hospital supplier prices).
CONCLUSION: We found a considerable drug-group-
related difference between consensus guidelines for anti-
emetic strategies and clinical practice. However, the total
expenditures did not vary significantly. We assume, that
the differences observed are due to patient-related factors
like history of nausea and emesis, tumor stage, tumor lo-
cation, sex, age, co-morbidity and alcohol consumption
rather than to chemotherapy. A computer-assisted anti-
emetic decision model (Emeto-Help) will be presented,
which includes both the drug-related emetogenic poten-
tial and the individual patient’s risk.
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